1-氨基-6-硝基茚 | 62658-54-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 1-氨基-6-硝基茚
• 英文名称: 6-nitro-indan-1-ylamine
• 英文别名: 6-Nitro-indan-1-ylamin；6-Nitro-1-amino-indan；6-Nitro-1-amino-hydrinden；6-nitro-1-aminoindan；6-Nitro-2,3-dihydro-1H-inden-1-amine
• CAS: 62658-54-2
• 化学式: C₉H₁₀N₂O₂
• 分子量: 178.191
• InChiKey: ROSHRXGQJBKFEG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  1-氨基-6-硝基茚 在 三乙胺 、 tin(ll) chloride 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 N-(6-amino-2,3-dihydro-1H-inden-1-yl)-4-ethylbenzenesulfonamide
  参考文献：
  名称：

  Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel

  摘要：

  A collection of aryl sulfonamido indanes based on the lead compound I was synthesized and evaluated for Kv1.5 inhibitory activity. Kv1.5 inhibitors have the potential to be atrium-selective agents for treatment of atrial fibrillation. (1R,2R)-1 has an IC50 of 0.033 mu M against Kv1.5 and is selective against other cardiac ion channels, including hERG. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.052
• 作为产物：
  描述：

  茚满 在 硫酸 、 ammonium acetate 、 硝酸 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 1-氨基-6-硝基茚
  参考文献：
  名称：

  Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel

  摘要：

  A collection of aryl sulfonamido indanes based on the lead compound I was synthesized and evaluated for Kv1.5 inhibitory activity. Kv1.5 inhibitors have the potential to be atrium-selective agents for treatment of atrial fibrillation. (1R,2R)-1 has an IC50 of 0.033 mu M against Kv1.5 and is selective against other cardiac ion channels, including hERG. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.052

文献信息

• ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY
  申请人：Tamura Yuusuke

  公开号：US20120015961A1

  公开（公告）日：2012-01-19

  The present invention provides, for example, a compound of the following formula (I): wherein R 1 is substituted amino and the like, R 2 is halogen and the like, R 3 is substituted or unsubstituted lower alkyl and the like, R A and R B are each independently hydrogen, substituted or unsubstituted lower alkyl and the like, R C and R D are each independently hydrogen, substituted or unsubstituted lower alkyl, or R C and R D together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle, and ring A is a carbocycle or a heterocycle, its pharmaceutically acceptable salt, or a solvate thereof as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-βproteins.

  本发明提供了以下式（I）的化合物，例如： 其中R 1 是取代氨基等， R 2 是卤素等， R 3 是取代或未取代的较低烷基等， R A 和R B 各自独立地是氢、取代或未取代的较低烷基等， R C 和R D 各自独立地是氢、取代或未取代的较低烷基，或R C 和R D 与它们连接的碳原子一起可以形成取代或未取代的碳环，以及 环A是碳环或杂环， 其药学上可接受的盐，或其溶剂合物作为由淀粉样蛋白β的产生、分泌和/或沉积引起的疾病的治疗剂。
• Diamino thiazoloindan derivatives and their use
  申请人：Sterling Jeffrey

  公开号：US20050197365A1

  公开（公告）日：2005-09-08

  The subject invention provides a compound having the structure: wherein Y is O, NR 3 R 4 or NOR 6 ; R 3 is H, alkyl, aralkyl, alkynyl, trifluoroacetyl, t-butoxycarbonyl or an acyl group; R 4 is H, alkyl, aralkyl, or alkynyl; R 6 is H or C 1 -C 4 alkyl; R 1 and R 2 are each independently H, alkyl, aralkyl, or alkynyl; the curved line drawn from S to the center of the phenyl ring and the straight line drawn from N to the center of the ring indicate that S and N are part of a 5 membered ring which shares two carbons with the phenyl ring; and the dashed line drawn from the carbon atom on the cyclopentyl ring to Y represents a bond when Y is O or NOR 6 and is absent when Y is NR 3 R 4 , and wherein wherein X is H or O; and R 5 is H, alkyl, trifluoroacetyl, t-butoxycarbonyl or an acyl group, or an enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof, a process for preparing the compounds and a method of treating Parknison's disease, multiple sclerosis or depression with the compounds of the invention.

  本发明提供一种具有以下结构的化合物：其中Y为O、NR3R4或NOR6；R3为H、烷基、芳基烷基、炔基、三氟乙酰基、叔丁氧羰基或酰基；R4为H、烷基、芳基烷基或炔基；R6为H或C1-C4烷基；R1和R2各自独立地为H、烷基、芳基烷基或炔基；从S到苯环中心画的弯线和从N到环中心画的直线表示S和N是一个共享两个碳原子的5元环的一部分；从环戊基环上的碳原子到Y画的虚线表示Y为O或NOR6时为键，当Y为NR3R4时则不存在该键；其中X为H或O；R5为H、烷基、三氟乙酰基、叔丁氧羰基或酰基，或其对映体、互变异构体或药学上可接受的盐，以及制备该化合物的方法和使用该化合物治疗帕金森病、多发性硬化症或抑郁症的方法。
• Ingold; Piggott, Journal of the Chemical Society, 1923, vol. 123, p. 1475,1485
  作者：Ingold、Piggott

  DOI：——

  日期：——
• Conformational analogs of antihypertensive agents related to guanethidine
  作者：R. F. Borne、M. L. Forrester、I. W. Waters

  DOI：10.1021/jm00216a007

  日期：1977.6

  In an effort to clarify the conformational requirements, if any, of agents producing adrenergic neuronal blockade through mechanisms similar to guanethidine, the synthesis and pharmacological evaluation of 15 analogues of cinnamylguanidine are described. These analogues represent derivatives in which the distance between the center of the ring system and the guanidinium nitrogen atom varies from 3.9 to 6.2 A. While conformational relationships could not be defined in this study, three analogues (3, 4, and 5) were apparently more potent than guanethidine in the in vitro assay employed.
• Ingold; Piggott, Journal of the Chemical Society, 1923, vol. 123, p. 1482,1508
  作者：Ingold、Piggott

  DOI：——

  日期：——